



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

(H)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/211,315	12/14/98	BOYLE	W A-451-G

US PATENT OPERATIONS/RBW
DEPT 430 M/S 27-4-A
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS CA 91320-1799

HM12/0210

EXAMINER
CARLSON, K

ART UNIT	PAPER NUMBER
1652	3

DATE MAILED: 02/10/99

Please find below and/or attached an Office communication concerning this application or
proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

Applicant(s)

Examiner

Group Art Unit

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address—

Period of Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

- ☐ Responsive to communication(s) filed on _____.
- ☐ This action is **FINAL**.
- ☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- ☒ Claim(s) 1-36 is/are pending in the application.
- Of the above claim(s) _____ is/are withdrawn from consideration.
- ☐ Claim(s) _____ is/are allowed.
- ☐ Claim(s) _____ is/are rejected.
- ☐ Claim(s) _____ is/are objected to.
- ☒ Claim(s) 1-36 are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.
- ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119 (a)-(d)

- ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
 - ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been received.
 - ☐ received in Application No. (Series Code/Serial Number) _____.
 - ☐ received in this national stage application from the International Bureau (PCT Rule 1.7.2(a)).

*Certified copies not received: _____

Attachment(s)

- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- ☐ Interview Summary, PTO-413
- ☐ Notice of Reference(s) Cited, PTO-892
- ☐ Notice of Informal Patent Application, PTO-152
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☒ Other Notice to Comply in Sequence Disclosures

Office Action Summary

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Restriction to one of the following inventions is required under
35 U.S.C. 121:

- I. Claims 1, 2, and 4-15, drawn to nucleic acids encoding
osteoprotegerin binding protein, classified in class 536, subclass
23.1.
- II. Claims 3, 16-24, 28, 32, and 33, drawn to osteoprotegerin binding
protein and a method of detecting osteoprotegerin, classified in
class 530, subclass 350.
- III. Claims 25-27, drawn to antibodies against osteoprotegerin binding
protein and method of detecting osteoprotegerin binding protein,
classified in class 530, subclass 387.1.
- IV. Claims 29 and 30, drawn to a method of using osteoprotegerin
binding protein to assess candidate compounds to bind to
osteoprotegerin binding protein, classified in class 435, subclass
7.1.
- V. Claim 31, drawn to a method of using nucleic acids encoding
osteoprotegerin binding protein, classified in class 514, subclass
44.
- VI. Claim 35, drawn to a method of treating bone diseases with soluble
osteoprotegerin binding protein, classified in class 514, subclass
2.
- VII. Claim 36, drawn to a method of treating bone diseases with
antibody against osteoprotegerin binding protein, classified in
class 424, subclass 130.1.

Claim 34 links Inventions VI and VII. This claim will be examined with
Invention VI or Invention VII if Invention VI or VII is elected.

The inventions are distinct, each from the other because:

The nucleic acids of Invention I are related to the protein of Invention

II by virtue of encoding same. The DNA molecule has utility for the recombinant production of the protein in a host cell, as recited in the Claims of Invention I. Although the DNA molecule and protein are related since the DNA encodes the specifically claimed protein, they are distinct inventions because the protein product can be made by another and materially different process, such as by synthetic peptide synthesis or purification from the natural source. Further, the DNA may be used for processes other than the production of the protein, such as nucleic acid hybridization assay.

The nucleic acid of Invention I and the antibody of Invention III are related by virtue of the protein that is encoded by the nucleic acid and necessary for the production of the antibody. However, the nucleic acid itself is not necessary for antibody production and both are wholly different compounds having different compositions and functions. Therefore, these Inventions are distinct.

The proteins of Invention II are related to the antibodies of Invention III by virtue of being the cognate antigen, necessary for the production of antibodies. Although the protein and antibody are related due to the necessary steric complementarity of the two, they are distinct Inventions because the protein can be used in another and materially different process from the use for the production of the antibody, such as in a pharmaceutical composition in its own right, or to assay or purify the natural ligand of the protein (if the protein is itself a receptor), or in assays for the identification of agonists or antagonists of the receptor protein.

Inventions I and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Serial Number 09/211315
Art Unit 1814

§ 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as in a hybridization assay, for example.

The nucleic acids of Invention I is not used in any of the methods of Inventions IV, VI, or VII. Therefore, Invention I is patentably distinct from
5 Inventions IV, VI, and VII.

Inventions II and IV or VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as
10 claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as in either Inventions IV or VI or to make antibodies, for example.

The osteoprotegerin binding protein of Invention II is not used in the
15 methods of Inventions V or VII. Therefore, Invention II is patentably distinct from Inventions V and VII.

Inventions III and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced
20 with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as in purifying osteoprotegerin binding protein, for example.

The antibodies of Invention III is not used in any of the methods of Inventions IV, V, or VI. Therefore, Invention III is patentably distinct from
25 Inventions IV, V, and VI.

The methods of Inventions IV-VII utilize different agents and/or are

Serial Number 09/211315
Art Unit 1814

comprised of wholly different steps and have wholly different end results.
Therefore, the methods of Inventions IV-VII are patentably distinct one from
the other.


5 Applicant is reminded that upon the cancellation of claims to a non-
elected invention, the inventorship must be amended in compliance with 37
CFR 1.48(b) if one or more of the currently named inventors is no longer an
inventor of at least one claim remaining in the application. Any amendment of
inventorship must be accompanied by a diligently-filed petition under 37
10 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

**This application contains sequence disclosures that are encompassed by
the definitions for nucleotide and/or amino acid sequences set forth in 37
CFR 1.821(a)(1) and (a)(2).** However, this application fails to comply with
15 the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on
the attached Notice To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

20 Any inquiry concerning this communication or earlier communications from
the Examiner should be directed to Karen Cochrane Carlson, Ph.D. whose
telephone number is (703) 308-0034. The Examiner can normally be reached
daily except alternate Fridays from 7:30 A.M. to 5:00 P.M.

25 If attempts to reach the Examiner by telephone are unsuccessful, the
Examiner's supervisor, Mr. Robert Wax, can be reached at (703) 308-4216. The
OFFICIAL fax phone number for Group 1800 is (703) 308-4242.

30 Any inquiry of a general nature or relating to the status of this
application or proceeding should be directed to the Group 1800 receptionist
whose telephone number is (703) 308-0196.


KAREN COCHRANE CARLSON, PH.D.
PRIMARY EXAMINER